Moderna reports a 1.2 billion loss in Q1 2024 due to plummeting demand. To reassure investors, Moderna has announced the development of a “next-generation” COVID vaccine that promises to combat different strains of the virus.
Moderna Reports $1.2 Billion Loss Due to Decreased Demand for COVID Vaccine, Assures Investors of Development of ‘Next-Generation’ Vaccine to Address Emerging Strains
